2. Academic Validation
  3. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

  • Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015.
Michael Hedvat 1,  Dennis Huszar,  Andreas Herrmann,  Joseph M Gozgit,  Anne Schroeder,  Adam Sheehy,  Ralf Buettner,  David Proia,  Claudia M Kowolik,  Hong Xin,  Brian Armstrong,  Geraldine Bebernitz,  Shaobu Weng,  Lin Wang,  Minwei Ye,  Kristen McEachern,  Huawei Chen,  Deborah Morosini,  Kirsten Bell,  Marat Alimzhanov,  Stephanos Ioannidis,  Patricia McCoon,  Zhu A Cao,  Hua Yu,  Richard Jove,  Michael Zinda
Affiliations

Affiliation

  • 1 Molecular Medicine, Beckman Research Institute, Irell & Manella Graduate School of Biological Sciences, City of Hope Cancer Center, Duarte, CA 91010, USA.
PMID: 19962667 DOI: 10.1016/j.ccr.2009.10.015
Abstract

Persistent activation of STAT3 is oncogenic and is prevalent in a wide variety of human cancers. Chronic cytokine stimulation is associated with STAT3 activation in some tumors, implicating cytokine receptor-associated JAK family kinases. Using JAK2 inhibitors, we demonstrate a central role of Jaks in modulating basal and cytokine-induced STAT3 activation in human solid tumor cell lines. Inhibition of JAK2 activity is associated with abrogation of STAT3 nuclear translocation and tumorigenesis. The JAK2 Inhibitor AZD1480 suppresses the growth of human solid tumor xenografts harboring persistent STAT3 activity. We demonstrate the essential role of STAT3 downstream of Jaks by inhibition of tumor growth using short hairpin RNA targeting STAT3. Our data support a key role of JAK kinase activity in Stat3-dependent tumorigenesis.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10193
    99.91%, JAK1/2 Inhibitor
    JAK